Asian Stocks Rise as AI Chip Rally Lifts South Korea, Japan 
Asian Currencies Edge Higher as Soft US Inflation Weighs on Dollar 
Gold Prices Rise as Weak US Retail Sales Cut Fed Rate Hike Bets 
Bank of America to Buy Up to 49.9% Stake in Jio Credit for $1.92 Billion 
Aviva First-Half Operating Profit Jumps 24% as Direct Line Deal Boosts Growth 
US Dollar Slips as Weak Retail Sales Reduce Fed Rate Hike Bets 
US Dollar Slips as Softer PPI Data Eases Fed Rate Hike Expectations 
Thyssenkrupp Raises 2026 Profit Outlook as Steel and Materials Units Strengthen 
Trump Imposes New Tariffs on Drone Imports Over US Security Concerns 
Pandora Shares Rise as Q2 Results Beat Forecasts, 2026 Outlook Raised 
Alphabet Shifts AI Strategy Toward Commercial Growth, Goldman Sachs Says 
Gold Prices Retreat From Two-Month High as Softer Inflation Eases Fed Rate Hike Bets 
SMIC Shares Rally as Q2 Profit Surges 262% on Strong Chip Demand 
Lenovo Revenue Surges 43% as AI Demand Drives Record First-Quarter Growth 
Gold Prices Slip From Two-Month High as Inflation and Fed Outlook Drive Markets 
Asian Stocks Rally as Cooling US Inflation Boosts Fed Rate Outlook 
US Dollar Holds Firm as Fed Outlook and Iran Tensions Keep Markets on Edge 
Add as a preferred source on Google
Eli Lilly and Company revealed it will acquire Sigilon Therapeutics by buying all the remaining shares that it did not own. The goal for the move is to develop and provide long-term solutions for diabetes patients by gaining access to the Massachusetts-based biotech firm’s experimental cell therapies that can provide longer-term solutions for diabetes patients.
According to Reuters, as of March 27, Eli Lilly owns almost 8.44% stake in Sigilon Therapeutics. It will now purchase the rest of the shares to own 100% of the company. The pharmaceutical firm headquartered in Indianapolis will pay a total of $34.6 million in cash which is equivalent to $14.92 per share for the acquisition deal.
Moreover, Lilly said that under the agreement, the shareholders of Sigilon Therapeutics will also get an additional $111.64 per share once Eli Lilly achieved some developmental and regulatory milestones. The deal is expected to close by the third quarter of this year, and once completed, the pharma company will be able to freely access all of the latter’s proprietary cell therapy candidates that are under development for the treatment of type 1 diabetes.
Prior to the acquisition, Eli Lilly and Sigilon Therapeutics have been working together for years already. Their cooperation started in 2018 when the former invested $63 million in a licensing deal with Sigilon. The investment was for the development of cell therapies for type 1 diabetes.
"Despite significant advancement in treatment for people living with type 1 diabetes, many continue to live with a high disease burden every day," Eli Lilly’s group vice president, diabetes, obesity and cardiometabolic research, Ruth Gimeno, Ph.D., said in a press release. "By combining Sigilon's talent and expertise in cell therapy with the knowledge and skills of Lilly's research and development teams, we will enhance opportunities to create innovative islet cell therapy solutions to improve the care of people living with diabetes."
Sigilon Therapeutic’s chief executive officer, Dr. Rogerio Vivaldi, M.D., also commented regarding the acquisition deal, "This agreement represents the culmination of the important work led by our research and development team to continue advancing SIG-002 at Lilly – the preeminent leader in the treatment of diabetes."
Finally, the Sigilon chief further said, “With deep industry expertise, Lilly is well-positioned to apply its industry-leading clinical and technical capabilities to harness the full potential of SIG-002 for the benefit of patients and their caregivers."
Photo by: Eli Lilly Press Release
